Compare SONO & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | NUVB |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2018 | N/A |
| Metric | SONO | NUVB |
|---|---|---|
| Price | $19.03 | $8.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $17.00 | $9.63 |
| AVG Volume (30 Days) | 1.6M | ★ 10.2M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,443,276,000.00 | $26,748,000.00 |
| Revenue This Year | $4.35 | $283.17 |
| Revenue Next Year | $7.90 | $340.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $7.63 | $1.54 |
| 52 Week High | $19.15 | $8.70 |
| Indicator | SONO | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 66.78 | 76.08 |
| Support Level | $18.16 | $7.46 |
| Resistance Level | $19.07 | $8.24 |
| Average True Range (ATR) | 0.65 | 0.62 |
| MACD | 0.19 | 0.13 |
| Stochastic Oscillator | 96.07 | 97.20 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.